

# Accelerating global development with an Asian oncology platform

ASLAN Pharmaceuticals is a clinical-stage oncology-focused biopharma company targeting cancers that are both highly prevalent in Asia and orphan indications in the United States and Europe

## Developing in Asia for global markets

- Strategically positioned in Asia with access to larger patient population where target cancers are prevalent
- Development platform in Asia enables acceleration of drug development and generation of data suitable for submission to regulators in US, Europe and Japan
- Few, if any, approved therapies in biliary tract cancer
- Experienced global management team with deep local relationships and extensive knowledge of target diseases
- Building commercial organisation in China and planning to build in US

## Quick facts

### Ticker

- NASDAQ: ASLN
- TPEX: 6497

(Each US ADS equivalent to 5 TPEX common shares)

### Shares outstanding

160,248,940

### Market Cap

US\$177M

(8 November 2018, NASDAQ)

### Cash

US\$34.8M

(30 September 2018)

## Varlitinib (ASLAN001)

Potential to be the first targeted therapy approved for biliary tract cancer

- Highly potent, oral, reversible, small molecule pan-HER inhibitor that targets the human epidermal growth factor receptors HER1, HER2, HER3 and HER4
- Demonstrated activity in biliary tract, gastric, breast and colorectal cancer. Two phase 2 trials completed, over 600 patients dosed
- Low levels of toxicity compared to other pan-HER inhibitors
- Competitive efficacy with 60% response rate demonstrated in second line HER2+ breast cancer
- Currently no approved targeted therapies for biliary tract cancer which affects more than 200,000 people in Asia every year
- Received Orphan Drug Designation from the US FDA for biliary tract cancer
- Biliary tract cancer: pivotal TreeTopp trial enrolment completed in early 2019, topline data expected in 2H 19

## ASLAN003

Oral DHODH inhibitor with potential to be first-in-class therapy for acute myeloid leukaemia (AML)

- Potent inhibition of DHODH, binding affinity up to two orders of magnitude stronger than first generation inhibitors
- Promotes differentiation of blast cells in multiple cell lines that are unresponsive to ATRA
- Lack of toxicities associated with first generation inhibitors and other AML therapies
- Received Orphan Drug Designation from the US FDA for AML
- Interim data from phase 2 trial in relapsed or refractory AML patients presented at ASH 2018
- Preclinical studies in triple negative breast cancer and hepatocellular carcinoma underway
- Part 1 readout 1H 19

## ASLAN004

IL-4R / IL-13R inhibitor with the potential to be best-in-class therapy for atopic dermatitis and asthma

- Potently inhibits signaling of both IL-4 and IL-13 receptors which are central to the allergic response in atopic dermatitis and asthma
- By targeting IL-13R $\alpha$ 1, a receptor with a narrower cellular distribution than the IL-4 receptor, it has the potential to offer both a lower dose and lower dosing frequency than current alternatives for target indications
- Phase 1 atopic dermatitis single ascending dose study expected to complete in 1H 19

Programs	Discovery	Preclinical	Phase 1	Phase 2	Pivotal	Key Milestones
<b>Global rights</b>						
<b>Varlitinib</b> <i>Pan-HER inhibitor</i>	Biliary tract cancer (2nd line)					Topline data 2H 19
	Biliary tract cancer (1st line)					
<b>ASLAN003</b> <i>DHODH inhibitor</i>	AML					Part 1 readout 1H 19
<b>ASLAN004</b> <i>IL4R/IL13R inhibitor</i>	Atopic dermatitis					SAD completion 1H 19
	Asthma					
<b>Partnered programs</b>						
<b>ASLAN002</b> <i>RON/MET inhibitor</i> <i>Partnered with BMS</i>	Solid tumors					

## Management

**Dr Carl Firth**  
Chief Executive Officer

**Dr Mark McHale**  
Chief Development Officer  
and Head of R&D

**Dr Chih-Yi Hsieh**  
Chief Medical Officer

**Jeff Tomlinson**  
Chief Business Officer

**Ben Goodger**  
General Counsel

**Kiran Asarpota**  
VP Finance

**Stephen Doyle**  
VP Commercial and GM China

## Major partnerships



## Analyst coverage

**Edward Tenthoff**  
Piper Jaffray

**Jonathan Chang**  
Leerink Partners

**Raghuram Selvaraju**  
H C Wainwright & Co

**Robert Hazlett**  
BTIG

**John Chang**  
President Capital Management Corp

## Headquarters

83 Clemenceau Avenue  
#12-03 UE Square  
Singapore 239920  
+65 6222 4235  
contact@aslanpharma.com

## Investor contact

**Robert Uhl**  
Westwicke Partners  
+1 858 356 5932  
robert.uhl@westwicke.com

## Investor contact (Taiwan)

**Michael Chiang**  
ASLAN Pharmaceuticals  
+886 2 2758 2767  
investor-taiwan@aslanpharma.com

## Media contact

**Emma Thompson**  
Spurwing Communications  
+65 6340 7287  
emma@spurwingcomms.com